Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

165
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
165
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Special consideration: commentary on the 2025 FDA Bioanalytical Method Validation for Biomarkers.

Bioanalysis·2025
Same author

Urinary Kidney Injury Biomarker Profiles in Healthy Individuals and After Nephrotoxic and Ischemic Injury.

Clinical pharmacology and therapeutics·2025
Same author

eTRANSAFE: Building a sustainable framework to share reproducible drug safety knowledge with the public domain.

F1000Research·2022
Same author

Perspectives on statistical strategies for the regulatory biomarker qualification process.

Biomarkers in medicine·2021
Same author

Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel.

Open heart·2021
Same author

Qualification of translational safety biomarkers.

Experimental biology and medicine (Maywood, N.J.)·2021
Same journal

Nicotinamide adenine dinucleotide phosphate oxidase 4 in lung disease: a review of its biology and therapeutic potential.

Experimental biology and medicine (Maywood, N.J.)·2026
Same journal

Phenotypic profiling of Pathogen Box compounds MMV667494 and MMV028694 in bloodstream-form <i>Trypanosoma brucei brucei</i>.

Experimental biology and medicine (Maywood, N.J.)·2026
Same journal

High systolic blood pressure and stroke: evidence from the NHANES 1999-2023 and global burden of disease 2021.

Experimental biology and medicine (Maywood, N.J.)·2026
Same journal

Scaling human liver microphysiological systems: implementing a higher-throughput liver acinus microphysiological system platform.

Experimental biology and medicine (Maywood, N.J.)·2026
Same journal

Race, oxygen exposure, and retinopathy of prematurity: re-examining a persistent epidemiologic paradox.

Experimental biology and medicine (Maywood, N.J.)·2026
Same journal

Peripheral immune cells and glycation indices as potential diagnostic biomarkers in amyotrophic lateral sclerosis.

Experimental biology and medicine (Maywood, N.J.)·2026
See all related articles

Related Experiment Video

Updated: Feb 18, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.5K

Preclinical biomarker qualification.

John-Michael Sauer1, Amy C Porter1, 1

  • 1Critical Path Institute, 1730 E. River Road, Tucson, AZ 85718, USA.

Experimental Biology and Medicine (Maywood, N.J.)
|November 25, 2017
PubMed
Summary
This summary is machine-generated.

Regulatory qualification of biomarkers is essential for drug development. This review summarizes past projects and discusses evolving strategies for using preclinical data to qualify clinical biomarkers, accelerating drug discovery.

Keywords:
Biomarkercontext of usedrug development toolpreclinicalregulatory qualificationsafety

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.3K

Related Experiment Videos

Last Updated: Feb 18, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.5K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.3K

Area of Science:

  • Biomarker development and regulatory science
  • Translational medicine
  • Drug development processes

Background:

  • Biomarkers are crucial for assessing drug safety and efficacy in preclinical and clinical studies.
  • Regulatory qualification by agencies like the FDA, EMA, and PMDA is necessary for routine biomarker application.
  • Consortia play a key role in accelerating biomarker qualification through stakeholder collaboration.

Purpose of the Study:

  • To review the history and learnings from three nonclinical biomarker qualification projects.
  • To discuss the transition of preclinical biomarker projects into clinical qualification.
  • To outline current strategies for using nonclinical data in the translational qualification of clinical biomarkers.

Main Methods:

  • Summarizing historical nonclinical biomarker qualification examples.
  • Analyzing the progression of preclinical to clinical biomarker qualification.
  • Reviewing current approaches for translational biomarker qualification.

Main Results:

  • Learnings from three past nonclinical biomarker qualification projects are detailed.
  • The evolving role of preclinical qualification in clinical biomarker qualification is discussed.
  • Novel approaches to improve the biomarker qualification process are presented.

Conclusions:

  • Biomarker qualification is a critical step in drug development, requiring robust data packages for regulatory approval.
  • The use of preclinical data in translational qualification is advancing, mirroring drug development candidate approval processes.
  • Collaborative efforts and novel strategies are essential to streamline and enhance biomarker qualification for faster drug development.